Third-Party Tested ≥98% HPLC Purity — USA Shipped

Weight Management Research Guide

Tesamorelin: Dosage, Benefits & Research Guide

Also known as: TH9507, stabilized GHRH analog

Key Facts

Tesamorelin is a weight management research peptide (C223H370N72O69S, MW 5195.91 g/mol). Synthetic GHRH analogue studied for visceral fat reduction and metabolic health. It is supplied as a lyophilized powder for laboratory and in-vitro research use only — not for human consumption.

Classification Stabilized growth-hormone-releasing hormone analog
Molecular Formula C223H370N72O69S
Molecular Weight 5195.91 g/mol
CAS Number 901758-09-6
Research Half-Life Short (~26–38 minutes) but resistant to enzymatic degradation
Form Lyophilized powder
Research Category Weight Management

What is Tesamorelin?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the 44-amino acid human GHRH sequence with a trans-3-hexenoic acid modification at the N-terminus. It acts by binding to GHRH receptors on anterior pituitary somatotroph cells, stimulating pulsatile growth hormone (GH) release while preserving the natural hypothalamic-pituitary feedback axis. Tesamorelin received FDA approval (marketed as Egrifta) for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, based on pivotal trials demonstrating approximately 15-18% reduction in visceral adipose tissue over 26 weeks (Falutz et al., JAMA 2007). Beyond lipodystrophy research, studies published in Annals of Neurology (Baker et al., 2012) suggest tesamorelin may improve cognitive function in older adults with mild cognitive impairment by modulating IGF-1 levels in the central nervous system. Compared to direct GH administration, tesamorelin preserves physiological GH pulsatility rather than creating supraphysiological sustained GH levels, which research indicates may reduce the risk of insulin resistance associated with exogenous GH. Additional preclinical work has explored its role in peripheral nerve regeneration models. The lyophilized powder should be stored at controlled room temperature (20-25C) or refrigerated; reconstitute with sterile water and use within 24 hours or refrigerate for up to 14 days. This peptide is studied by endocrinology research labs, HIV metabolism centers, and neuroscience institutions investigating GH-IGF-1 axis modulation.

Tesamorelin Research Applications

In published and preclinical research, Tesamorelin has been studied across the following areas:

  • HIV-associated lipodystrophy and visceral fat reduction
  • Peripheral nerve regeneration
  • Mild cognitive impairment research
  • Cardiovascular health through metabolic markers

Tesamorelin in Research: Reconstitution & Study Concentrations

Tesamorelin is a stabilized GHRH analog studied for its effect on the GH/IGF-1 axis and visceral adipose tissue. Research concentrations are model-specific; the lyophilized peptide is reconstituted with bacteriostatic water for laboratory use only.

Worked example: a 5mg vial reconstituted with 2 mL of bacteriostatic water yields 2.50 mg/mL.

Open the reconstitution calculator

How Tesamorelin Compares

Researchers frequently evaluate Tesamorelin alongside related compounds:

Tesamorelin — Frequently Asked Questions

What is Tesamorelin and how does it work?
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification at the N-terminus. It binds to GHRH receptors on pituitary somatotroph cells, stimulating the pulsatile release of endogenous growth hormone. This mechanism has been studied for its downstream effects on IGF-1 levels, visceral adipose tissue metabolism, and hepatic lipid profiles.
What research has been done on Tesamorelin?
Tesamorelin has been studied in multiple clinical trials for HIV-associated lipodystrophy, where it received FDA approval (as Egrifta). Published research in the Journal of Clinical Endocrinology & Metabolism demonstrated significant reductions in visceral adipose tissue. Additional studies have explored its effects on peripheral nerve regeneration, mild cognitive impairment in aging populations, and non-alcoholic fatty liver disease biomarkers.
How does Tesamorelin compare to Sermorelin?
Both tesamorelin and sermorelin are GHRH analogues, but tesamorelin's trans-3-hexenoic acid modification provides greater resistance to enzymatic degradation, resulting in higher bioavailability and more potent GH release per dose in research models. Sermorelin is a shorter fragment (amino acids 1-29 of GHRH), while tesamorelin includes the full 44-amino acid sequence with the N-terminal modification.
What is the recommended reconstitution protocol for Tesamorelin?
For this 5mg vial, add 1 mL of bacteriostatic water to yield a concentration of 5mg/mL. Draw 20 units on a 1mL insulin syringe for a 1 mg dose. Inject BAC water slowly along the inner vial wall — do not shake. Allow the powder to dissolve fully (2–5 minutes). Administer AM and PM. Use 5 days on, 2 days off. Refrigerate reconstituted solution at 2–8°C and use within 30 days.
Is Tesamorelin legal to buy for research?
Tesamorelin is sold in the United States as a research chemical for laboratory and in-vitro use only. It is not approved by the FDA for human use and is not sold for human consumption. Researchers are responsible for compliance with all applicable federal, state, and institutional regulations.
How is Tesamorelin reconstituted for research use?
Tesamorelin ships as a lyophilized (freeze-dried) powder and is reconstituted with bacteriostatic or sterile water before use in research. The volume of solvent added determines the working concentration — use the Elyte reconstitution calculator to derive the exact concentration for a given vial size and solvent volume.
Does Tesamorelin come with a Certificate of Analysis?
Yes. Every batch of Tesamorelin from Elyte Peptides ships with a third-party Certificate of Analysis (COA) documenting identity and HPLC purity (≥98%), so research results can be traced to a verified lot.

Research References

  1. Falutz J et al. Tesamorelin, a GHRH analogue, in patients with excess abdominal fat. NEJM 2007.
All research guides